The pathogenicity of the M9 mutant of Semliki Forest virus in immune-compromised mice.
The role of immune mechanisms in the pathogenicity of the M9 mutant of Semliki Forest virus (SFV) has been examined by the use of immune-deficient and immune-suppressed mice. In immune-competent BALB/c and C57BL/6 mice, the lesions in the central nervous system (CNS) were characterized by acute demyelinating meningoencephalomyelitis. Myelin vacuolation and demyelination were more severe in BALB/c mice than in mice with a C57BL background. The mortality was 12% and 29% respectively. Treatment with cyclophosphamide or sodium aurothiomalate did not greatly alter the type of lesion produced, although mortality was increased. Lesions were less severe in nude (T-lymphocyte-deficient) mice and more severe in beige (natural killer cell-deficient) mice than in most immune-competent mice. Mortality was marginally increased in nude mice but not in beige mice. Demyelination in nude mice was followed rapidly by remyelination. Immune modification did not significantly alter the titres of virus in the brain at 7 days post-infection and infectious virus had been cleared from the brain by 14 days in all cases. Degenerating oligodendrocytes were detected in the CNS of all immune-modified mice examined at day 7. This study therefore suggests that both immune mechanisms and destruction of oligodendrocytes play a role in the production of demyelination by M9.
D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis; D003711:Demyelinating Diseases / Q000276:immunology / Q000382:microbiology; D007108:Immune Tolerance; D007121:Immunocompetence; D007153:Immunologic Deficiency Syndromes / Q000276:immunology / Q000382:microbiology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008819:Mice, Nude; D009154:Mutation; D009500:Neutralization Tests; D012672:Semliki forest virus / Q000276:immunology / Q000472:pathogenicity*; D013997:Time Factors; D014036:Togaviridae Infections / Q000276:immunology / Q000382:microbiology*
D000914:Antibodies, Viral